Ignite Creation Date:
2025-12-24 @ 2:53 PM
Ignite Modification Date:
2026-01-13 @ 3:13 PM
Study NCT ID:
NCT03402659
Status:
COMPLETED
Last Update Posted:
2021-10-27
First Post:
2018-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
Sponsor:
EIP Pharma Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-12-29
Start Date Type:
ACTUAL
Primary Completion Date:
2019-06-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-07-31
Completion Date Type:
ACTUAL
First Submit Date:
2018-01-11
First Submit QC Date:
None
Study First Post Date:
2018-01-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-08-26
Results First Submit QC Date:
None
Results First Post Date:
2021-10-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-09-28
Last Update Post Date:
2021-10-27
Last Update Post Date Type:
ACTUAL